(Part four of a four part series – Read part three)
The reason companies offering psychedelic assisted therapy only use ketamine is that it is the only one with medical approval at the moment. While psilocybin and MDMA are extremely promising, but they are still in clinical research.
MDMA is likely to be approved sometime in 2024, initially for the treatment of PTSD, and psilocybin is expected to follow soon as it is currently in clinical trials.
The three substances can be effective in treating multiple conditions. awakens AWKNF dr ben sessa predicts that within 5 to 10 years all three will “be available in different ways for all diseases”. In fact, he believes so Short-acting ketamine is effective for addiction, “breaks a stick, penetrates a rigidity” and therefore “will always have its place.”
The conversation about psychedelics as possible preventive treatments in mental disorders, before a person becomes ill, already happens by term behavioral psychedelics.
“Psychedelics are very good at promoting spontaneous lifestyle changes. There’s pretty solid evidence from large population studies that people who take it Free time in a non-hedonic, pseudo-clinical way have better physical mental health than people who don’t,” explained Dr. sessa
These drugs tend to create a sense of connectedness and community with others as well as a positive lifestyle.
dr Sessa says psychedelics play a role within the non-clinical population. “It shouldn’t just be people who get sick. There should be retreats, wellness centers where people can pursue personal growth and development, community growth and development, family growth that protect them and protect them from mental health problems. That’s a very interesting idea.”
As such, psychedelics can help people change their behavior and choose healthier lifestyles. youngest research…
